Metabolic dysfunction-associated steatotic liver disease

This study tests whether taking a low dose of niacin (vitamin B3) after meals can help reduce fat stored in the liver for people with metabolic fatty liver disease (MASLD). Researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The goal is to see if niacin can r…

This study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 …

This study tests whether dihydroartemisinin, a drug used for malaria, can safely reduce liver fat in adults with Metabolic Associated Fatty Liver Disease (MAFLD). About 30 participants aged 18 to 45 will take the drug three times daily for 12 weeks. The main goal is to measure ch…

This study tests whether limiting food intake to an 8-hour window each day (without counting calories) can reduce liver fat in people with obesity and a type of fatty liver disease called MASLD. Seventy-two participants will either follow this eating pattern plus standard advice,…

This Phase 2a trial is testing a new drug called ALN-PNP, alone or with a weight-loss drug (tirzepatide), in 204 adults with a specific genetic form of fatty liver disease (MASLD). The goal is to see if lowering a certain liver protein can reduce liver fat. Participants must have…

This phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…

This large phase 3 study is testing whether two drugs, tirzepatide and retatrutide, can prevent major liver complications in 4,500 adults with high-risk metabolic fatty liver disease (MASLD). Participants are randomly assigned to receive one of the drugs or a placebo for about 4 …

The UNMASK study is testing whether a 16-week program of Mediterranean diet and regular exercise can reduce liver fat and scarring in people with metabolic fatty liver disease (MASLD). Researchers will enroll 450 adults and track changes in liver health using scans and blood test…

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by 70%, can help reverse fatty liver disease (MASH) in people with obesity. Researchers will compare ESG plus lifestyle changes to lifestyle changes alo…

This Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…

This study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…

This Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …

This study investigates whether reducing calories to lower fat in the liver and muscles can improve how the body responds to insulin. Researchers will measure changes in insulin sensitivity and fat levels in 250 healthy but insulin-resistant adults with a family history of type 2…

This study tests whether the drug maridebart cafraglutide can reduce liver fat and body weight in adults who are overweight or obese and have high liver fat. Participants will also follow a reduced-calorie diet and increase physical activity. The trial involves 180 adults and las…

This study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main …

This study tests a program called MiWeigh that helps people with obesity and related conditions like diabetes or high blood pressure lose weight. Participants get a personalized plan from a doctor, access to a website, and weekly check-ins. The goal is to see if this approach lea…

This study tests whether eating 50 grams of peanuts daily for 12 weeks can improve liver markers and gut health in adults with metabolic fatty liver disease (MASLD). 125 participants will be randomly assigned to either eat peanuts or stick to their regular diet. Researchers will …

This phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…

This Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…

This study tests a new drug, pegozafermin, in 1,350 adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if the drug can improve scarring or resolve liver inflammation without making the disease worse over 52 weeks. Par…

This study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…

This study tests whether rosuvastatin, a cholesterol-lowering drug, can safely slow or stop liver scarring (cirrhosis) compared to a placebo. About 256 adults with compensated cirrhosis will take the drug or placebo for 2 years. The main goal is to measure changes in liver stiffn…

This study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a p…

This study tests two diet approaches—essential amino acids and a low-sugar diet—in teens aged 11-17 with fatty liver disease and heart risk. The goal is to reduce liver fat and improve health. Participants will be assigned to one or both diets over time to find the best treatment…

This study tests whether a daily orange peel fermentation supplement can lower body fat in 124 overweight adults with fatty liver. Participants take one sachet per day for two months. Researchers will measure changes in body fat, cholesterol, and other health markers.

This study compares two approaches for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity. Half of the 48 participants will receive vertical sleeve gastrectomy surgery along with lifestyle counseling, while the other half will get lifestyle…

This early-stage study tests whether bicalutamide, a drug that blocks male hormones, can improve liver health in women aged 18-42 who have both polycystic ovary syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD). About 50 participants will receive either bicalutamide or…

This study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). The trial will involve 144 adults with biopsy-confirmed NASH and liver scarring. Participants will …

This study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS…

This study tests whether a 4-week ketogenic diet before liver surgery can reduce fat in the liver and lower the need for blood transfusions. About 124 adults with fatty liver and colorectal cancer that spread to the liver will either follow the diet or get standard dietary advice…

This study tests whether adding a physical activity program to standard care can improve health in older women who have three conditions: underactive thyroid (hypothyroidism), glaucoma (high pressure in the eyes), and fatty liver. Researchers will measure changes in eye pressure,…

This study tests an investigational drug called TGM-312-SC01, given as a shot, for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition. It first checks safety and drug levels in healthy adults, then in people with MASH. The trial is currently recrui…

This Phase 2 trial tests a drug called ALN-HSD, which uses gene silencing to target liver scarring in people with MASH, a fatty liver disease that can lead to cirrhosis. The study enrolls 120 adults with genetic risk factors and moderate-to-severe liver fibrosis. Researchers will…

This study tests a new drug called HU6 for people with MASH, a serious fatty liver disease. About 180 adults aged 30 and older will receive either HU6 or a placebo to see if the drug safely reduces liver fat. The trial lasts 26 weeks and focuses on safety and how well the drug wo…

This study tests whether aerobic exercise in simulated altitude (normobaric hypoxia) can improve body composition and metabolism in people with MASLD, a type of fatty liver disease. Twenty sedentary adults with MASLD will walk on a treadmill for 8 weeks, either in mild altitude o…

This study is testing whether adding extra virgin olive oil to the diet can improve liver fat, inflammation, and blood sugar in people with MASLD (fatty liver disease) who are overweight. Researchers will give 60 participants either 3 or 9 tablespoons of olive oil daily for a per…

This study tests whether carbocisteine, a drug already used for coughs, can safely reduce fat buildup in the liver of people with nonalcoholic fatty liver disease (NAFLD). About 46 adults with fatty liver will take the drug and be monitored for changes in liver fat via ultrasound…

This study tests whether resmetirom, a drug already approved for another liver condition, can safely reduce liver fat in people with HIV who also have fatty liver disease (MASLD). About 120 adults with well-controlled HIV will take either resmetirom or a placebo daily for 24 week…

This study tests whether a daily probiotic capsule can reduce liver fat and stiffness in adults with moderate fatty liver disease (MASLD). Sixty participants will take either the probiotic or a placebo for 6 months, with liver scans and blood tests at the start, 3 months, and 6 m…

This study tests an experimental drug called ALN-CIDEB in adults with fatty liver conditions (MASLD or MASH). The main goal is to check safety and tolerability, and also to see if the drug can reduce liver fat. About 132 participants will receive either the drug or a placebo. Thi…

This study tests if weight-loss surgery is better than standard medical treatment for making nonalcoholic steatohepatitis (NASH) with advanced liver scarring disappear without making the scarring worse. It involves 100 obese adults with NASH and significant liver fibrosis. Partic…

This phase 3 trial tests a drug called efimosfermin alfa in 1250 adults with MASH (a fatty liver disease) and moderate liver scarring. The main goal is to check safety and side effects. Participants will receive either the drug or a placebo, and researchers will monitor liver hea…

This Phase 3 trial tests whether efimosfermin alfa can improve liver scarring and reduce inflammation in people with MASH (a type of fatty liver disease). About 1,200 adults with moderate-to-severe liver fibrosis will receive the drug or a placebo for 52 weeks. The goal is to see…

This 12-week study tests whether reishi mushroom supplements can improve liver health in 102 adults with metabolic fatty liver disease. Participants will take reishi mushroom powder or a placebo, alongside a probiotic-rich diet. Researchers will measure changes in liver enzymes, …

This study tests whether a machine that keeps donated livers working outside the body can help doctors safely use livers that were previously considered too risky for transplant. About 186 adults on the liver transplant waiting list will be randomly assigned to either receive a s…

This study tests whether a 5:2 intermittent fasting diet (eating only about 600 calories on two non-consecutive days each week) can reduce liver fat in people with metabolic dysfunction-associated steatotic liver disease (MASLD). 120 adults with obesity and significant liver fat …

This study tests an experimental drug called ALN-PNP in healthy adults and people with a liver condition called MASLD who have a specific gene variant. The main goal is to check safety and how the body handles the drug. It is a first-in-human trial, so the drug is not yet approve…

This study is testing whether a multi-strain probiotic supplement, taken alongside standard lifestyle advice, can improve liver health in people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The trial will enroll 80 adults with elevated liver enzymes and …

This early-stage trial tests an experimental drug called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive three monthly injections of either the drug or a placebo. The main goal is to check safety and how the drug moves through the…

This study looks at whether adding aerobic or high-intensity interval exercise to a low-glycemic Mediterranean diet can lower inflammation better than diet alone. Researchers will enroll 90 adults aged 18-65 with obesity and non-alcoholic fatty liver disease. Participants will be…

This early-stage trial is testing whether a pasteurized gut bacterium called Akkermansia muciniphila can help people with metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. About 40 adults will take either a low, medium, or high dose…

This study tests whether a daily nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein can improve liver function and quality of life in adults with liver disease from chronic hepatitis C. Over 12 weeks, 26 participants will take either the s…

This study tests whether a daily injection of tesamorelin can safely reduce liver fat in adults with metabolic fatty liver disease (MASLD). About 120 participants will receive either the drug or a placebo for 52 weeks, along with lifestyle advice. The main goal is to measure chan…

This study tests a new, non-surgical procedure called Endoscopic Radial Compression Gastroplasty (ERCG) that uses a clip-and-loop system to reduce stomach size, helping with weight loss. It is for Chinese adults aged 18-65 with a BMI of 24.0-37.4 who have not succeeded with diet …

This study tests a new tablet called CS060380 for adults with non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. About 120 participants will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in liver fat using MRI and track a…

This study tests if eating only during an 8-hour window each day, along with a healthy diet and exercise, can reduce liver fat in people with non-alcoholic fatty liver disease. About 40 adults will be split into two groups: one follows the time-restricted eating plan plus standar…

This Phase 3 trial tests a drug called LAENNEC, made from human placenta, in people with chronic liver disease. It compares giving the drug as an intravenous drip versus a standard shot under the skin. The main goal is to see if the IV form lowers liver enzyme levels more effecti…

This study tests whether taking capsules of processed donor stool (fecal transplant) can help people with liver cirrhosis avoid serious infections and hospital stays. About 300 adults with alcohol-related or fatty liver cirrhosis will receive either the transplant or a placebo an…

This study tests whether a low dose of the thyroid hormone Synthroid can help treat nonalcoholic steatohepatitis (NASH), a serious liver condition common in Veterans. About 128 overweight or obese Veterans with NASH will take either Synthroid or a placebo daily for one year. The …

This study tests a new medicine called NNC4005-0001 to see if it is safe and tolerable for people with extra body weight and too much fat in the liver. About 60 adults will get either the medicine or a placebo (a dummy pill) just once. The study lasts about 7 to 8 months and focu…

This early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…

This study tests whether a gut-acting antibiotic called rifaximin-α can reduce liver fat in people with metabolic fatty liver disease (MASLD). About 60 adults will take either the drug or just follow diet and exercise advice for 24 weeks. The goal is to see if the drug safely low…

This study tests whether goserelin acetate, a drug that temporarily stops menstruation (like a short-term menopause), can reduce liver fat in women with endometriosis who also have fatty liver disease. Researchers will measure liver fat and stiffness using ultrasound in 62 women …

This pilot study tests whether milk thistle, an herbal supplement, can improve fatty liver disease in children aged 9 to 22. Twenty participants will receive either milk thistle capsules or a placebo, plus lifestyle advice. The goal is to see if milk thistle lowers liver enzymes …

This study tests whether empagliflozin (Jardiance), a drug used for diabetes, can reduce liver fat in teenagers with obesity and non-alcoholic fatty liver disease (NAFLD). Forty participants aged 16 to under 21 will receive either the drug or a placebo for 26 weeks. The main goal…

This study looks at whether the diabetes drug pioglitazone can improve how the liver processes energy in people with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Researchers will measure liver mitochondrial function using special tracers before and after 16 weeks…

This study compares an Indianized version of the Mediterranean diet to a standard low-fat diet for reducing liver fat in overweight children and teens with a fatty liver condition called MASLD. About 134 participants aged 8 to 18 will follow one of the two diets for 180 days. The…

This study tests an experimental pill called HP515 for people with non-alcoholic fatty liver disease (NAFLD). About 80 adults aged 18 to 65 with at least 10% liver fat will take the drug for 12 weeks. The main goal is to see if it reduces liver fat measured by MRI, while also che…

This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through …

This study tests whether a community health worker-led program can help Mexican-origin adults with fatty liver disease (MASLD) better understand their heart disease risk and make healthier lifestyle changes. About 45 participants and their family members or friends will take part…

This study tests whether a Mediterranean diet and regular walking can improve memory and thinking in adults with non-alcoholic fatty liver disease (NAFLD). 45 participants aged 18-42 will be split into three groups: general health advice, a structured Mediterranean diet, or the d…

This pilot study tests whether time-restricted intermittent fasting can lower liver fat in non-obese adults (BMI 23-30) with non-alcoholic fatty liver disease (NAFLD). Researchers will measure liver fat changes using advanced imaging and track quality of life. The goal is to find…

This study tests whether erdosteine, a drug usually used for lung conditions, can help people with nonalcoholic fatty liver disease. Fifty adults with fatty liver will receive either standard care (diet and exercise) or standard care plus erdosteine. Researchers will measure chan…

This study tests resmiterom, the first FDA-approved drug for MASH (a type of fatty liver disease), in 165 Pakistani patients. Researchers will check how safe it is and whether it improves liver health using non-invasive scans. The goal is to see if the drug works well in this spe…

This Phase 3 trial tests whether hydroxychloroquine, a drug used for malaria and autoimmune diseases, can improve nonalcoholic steatohepatitis (NASH), a type of fatty liver with inflammation. 210 adults with confirmed fatty liver and elevated liver enzymes will take either 200 mg…

This early-stage trial tests whether cilostazol, a drug used for leg pain, can help people with nonalcoholic fatty liver disease (NAFLD). About 50 adults with fatty liver will take the drug to see if it reduces liver fat and lowers fibrosis risk scores. The study aims to find a n…

This study tests a new medicine, IBI362, in 165 adults with MASH, a serious fatty liver disease that can lead to scarring. Participants will receive either a low dose, high dose, or a placebo for 60 weeks. The main goal is to see if the drug can improve liver health without makin…

This study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug …

This study tests a digital app that helps doctors guide patients with metabolic fatty liver disease (MAFLD) through diet and exercise plans. Researchers will enroll 2,000 adults aged 18–65 with a BMI of 24–35 and a confirmed MAFLD diagnosis. Participants use the app to track weig…

This phase 2 trial tests whether nicotinamide (a form of vitamin B3) can stop or reverse liver fibrosis in people with non-alcoholic fatty liver disease and obesity. Thirty adults will take either nicotinamide or a placebo daily for one year. Researchers will measure liver stiffn…

This study tests whether a daily ketone ester drink can reduce liver fat and improve how the body handles sugar in adolescents and young adults with obesity and a fatty liver condition called MASLD. Forty participants will be randomly assigned to receive either the ketone drink o…

This early-stage trial is testing whether giving a mix of healthy gut bacteria (from donors) to people hospitalized with serious liver disease is safe and tolerable. The study involves 24 adults with liver failure or cirrhosis who have low levels of certain gut metabolites. Resea…

This study aims to find the most effective amount of exercise to reduce liver fat in people with NASH, a serious liver disease. Researchers will compare different exercise doses in 45 sedentary adults aged 18-69 with NASH and early-stage liver scarring. The goal is to provide cle…

This study tests if a tube-like device called a stent, placed through a scope, can reverse gastric bypass surgery in 20 people who have serious complications like low blood sugar, blockages, or liver problems. The goal is to see if the stent works as well as surgery to fix these …

This study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can …

This early-stage trial is testing whether the antibiotic rifaximin can reduce liver fat in people with metabolic fatty liver disease. About 40 adults will take rifaximin pills three times daily for up to 48 weeks, while maintaining diet and exercise. The main goal is to see if li…

This study tests whether giving $80 per month in fruit and vegetable vouchers to families with food insecurity can improve liver health in children with MASLD (fatty liver disease). The study will enroll 48 children aged 6-17 who are already receiving care at UCSF clinics. Resear…

This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve ear…

This study aims to see which of two blood tests, eLIFT or FibroMeter, is better at finding advanced liver scarring (fibrosis) in people with fatty liver disease or alcohol-related liver disease. About 1,788 adults from primary care clinics will take both tests. The goal is to imp…

LiverSeek is a study testing an automated screening program for advanced liver fibrosis in people aged 50-75 with risk factors like diabetes or obesity. When a routine blood test is done, the lab system automatically calculates a fibrosis score and, if needed, orders additional t…

This study is testing a new, non-invasive liver scan called iLivTouch to see if it can accurately detect a serious liver condition called MASH in people who have both type 2 diabetes and fatty liver disease. The scan measures liver inflammation, fat, and stiffness without any nee…

This study is collecting blood samples from 575 adults with fatty liver disease to find new, noninvasive tests that can detect liver scarring (fibrosis). Currently, doctors rely on a painful liver biopsy to check for scarring, but this research aims to replace that with a simple …

This study is testing a new, non-invasive MRI scan (called cT1) to see if it can accurately diagnose NASH, a serious liver disease. Currently, doctors need to take a small sample of liver tissue with a needle (biopsy) to confirm the diagnosis. The study will compare the MRI resul…

This study tests a new endoscopic ultrasound method (EUS-SWQ) to measure liver stiffness and diagnose liver fibrosis (scarring) in people with chronic liver disease. Researchers will compare EUS-SWQ results with standard liver biopsy and FibroScan in 65 adults. The goal is to see…

This study is looking at whether a blood test called the Enhanced Liver Fibrosis (ELF) test can find early signs of fatty liver disease in people who are at high risk, such as those with diabetes, high blood pressure, or heart disease. Researchers will review medical records of 3…

This study is testing a new, non-invasive ultrasound device called the Hepatoscope to screen for liver scarring (fibrosis) and fatty liver in people at risk. Researchers will enroll 200 patients with risk factors like diabetes or elevated liver enzymes. Those with high stiffness …

This study is testing a new, portable device called LiverScope that uses magnetic fields to check the liver for disease, similar to an MRI but smaller and easier to use. Researchers want to see if LiverScope gives the same results as a standard MRI. About 26 adults with a type of…

This study tests whether a special ultrasound done during an endoscopy can accurately detect liver scarring in people with obesity and suspected non-alcoholic fatty liver disease. Researchers will compare this new method to standard tests and liver biopsy in 150 adults. The proce…

This study is testing whether measuring spleen stiffness with a special ultrasound probe can detect advanced liver scarring in people with metabolic fatty liver disease (MASLD). Researchers will follow 500 adults for up to several years to see if the test predicts serious liver p…

This study is testing whether combining new blood tests and stool analysis can detect liver fibrosis earlier than current methods. Researchers will follow 1200 adults referred to a community liver clinic. The goal is to identify advanced liver disease sooner and reduce unnecessar…

This study is testing whether advanced ultrasound techniques can accurately detect fatty liver disease (MASLD) in children aged 9 to 18. Researchers will compare ultrasound results to MRI scans and blood tests in 120 children with risk factors for the condition. If the ultrasound…

This pilot study is testing a new Thermoacoustic Enhanced Ultrasound device to measure fat in the liver. Researchers will compare the device's readings to the gold-standard MRI measurement in 49 adults with fatty liver disease. The goal is to develop a more accessible and afforda…

This study is testing a new ultrasound method to measure fat in the liver without needles or expensive scans. It involves 110 adults with or at risk for MASLD, a common liver condition linked to obesity and diabetes. If successful, this tool could make liver health checks easier …

This study compares two step-by-step approaches to diagnose advanced liver fibrosis in people with NAFLD (fatty liver disease). Both methods start with a simple blood test, then use a more advanced test only if needed, aiming to avoid invasive liver biopsies. About 1,045 particip…

This study is testing whether special ultrasound scans can accurately detect liver damage in children without needing a needle biopsy. Researchers will compare these scans to standard biopsy results in 550 children with various liver conditions. If the scans prove reliable, they …

This study is testing a new ultrasound technology called DeepUSFF to measure fat in the liver of people with metabolic fatty liver disease (MASLD). Researchers will compare the ultrasound results to MRI scans, which are the current gold standard. If the ultrasound works well, it …

This study is testing a new way to measure liver scarring using an endoscopic ultrasound with special software. About 300 adults with suspected liver disease will undergo this new scan, a standard liver biopsy, and another non-invasive test. The goal is to see if the new techniqu…

This study is testing a blood test called hepatomiR to see if it can predict when people with chronic liver disease will develop serious complications like fluid buildup in the belly, bleeding from the esophagus, or confusion from liver failure. Researchers will follow 156 outpat…

This study tests whether semaglutide (a drug used for diabetes and weight loss) can prevent weight gain and fatty liver disease in people who have recently had a liver transplant. About 50 adults who had a transplant 2 to 6 months ago will receive either semaglutide or a placebo.…

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study looks at whether high-intensity interval training (HIIT) can improve liver health in adults aged 18 to 59 who are overweight or have obesity. Thirty participants will either do HIIT for 8 weeks or continue their usual routine. The goal is to see if exercise can reduce …

This study tests whether a chatbot powered by large language models can help people with metabolic alcohol-related liver disease (MetALD) reduce their alcohol intake. About 50 adults in Hong Kong will use the chatbot for counseling. The main goal is to see if the approach is prac…

This study surveys physicians in China to understand how they diagnose and manage metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. It focuses on whether and how doctors assess liver fibrosis, a key indicator of disease severity. Th…

This study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…

This study follows 200 obese Chinese patients undergoing weight-loss surgery to understand how nonalcoholic fatty liver disease (NAFLD) progresses. Researchers will take liver biopsies during surgery and track health markers over time. The goal is to find better ways to predict a…

This study enrolls up to 15,000 children with known or suspected endocrine or metabolic disorders, along with their family members. Researchers will collect medical records, blood, saliva, and other samples to identify genetic changes linked to these conditions. The goal is to be…

This study looks at how the drug mirdametinib is absorbed and removed from the body in people with moderate or severe liver problems compared to those with normal liver function. It involves 32 adults and is for research only, not to treat any condition. The goal is to understand…

This study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for…

This study uses a device called FibroScan to measure liver stiffness and fat content in people with liver disease. The scan is non-invasive, like an ultrasound, and takes only a few minutes. Researchers aim to build a large database of these measurements to help improve future di…

This early-phase study tests a new way to use PET scans to measure inflammation in both the liver and brain at the same time. Researchers will scan 12 adults with fatty liver disease using two different tracers (18F-FDG and 18F-DPA-714) to see if the new method can reliably detec…

This observational study aims to see if frailty—a state of increased weakness and vulnerability—differs between men and women with MASLD (fatty liver disease). Researchers will track 140 participants over time using physical tests and questionnaires. No drugs or treatments are be…

This study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

This study looks at whether new MRI techniques can spot NASH, the serious form of fatty liver disease, without needing a liver biopsy. Researchers will scan 110 adults who already need a biopsy to see if the MRI can match the biopsy results. If successful, it could lead to a safe…

This study looks at 20 adults with psoriatic arthritis and fatty liver disease to see if the drug guselkumab can improve liver fat, joint swelling, and skin plaques. Participants will have two visits over 24 weeks to track changes. The goal is to understand shared disease mechani…

This study looks at whether people born with a low birth weight have a higher chance of developing non-alcoholic fatty liver disease (NAFLD) as adults. Researchers will compare 250 low-birth-weight adults with 50 normal-birth-weight adults using liver scans and other tests. The g…

This early-stage study is testing how the drug BMS-986435 behaves in the body and whether it is safe for people with mild to moderate liver problems compared to those with healthy livers. 24 adults will receive a single dose, and researchers will measure drug levels and monitor f…

This early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver pro…

This study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…

This early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrh…

This study compares people with non-alcoholic fatty liver disease (NAFLD) to healthy controls to understand how the immune system, metabolism, and gut bacteria differ. Researchers will also track what happens to liver health in NAFLD patients who undergo weight loss surgery. The …

This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to …

This study will screen 2,000 people with HIV for fatty liver disease using a painless ultrasound technique. The goal is to catch liver problems early and improve long-term care. Researchers will also track how different HIV medications affect liver health.

This early-stage study looks at how the liver handles two experimental drugs, AZD9550 and AZD6234, in people with moderate to severe liver problems compared to healthy volunteers. About 28 adults will receive a single injection of one drug. The goal is to see if liver impairment …

This study will follow 20,000 elderly people with fatty liver disease to learn what factors affect their health. Researchers will look at lifestyle, genetics, and environment to understand how the disease progresses. The goal is to create better risk assessment tools and preventi…

This study aims to see how common fatty liver disease (MASLD) is in people with underactive thyroid (hypothyroidism) who do not have diabetes. Researchers will use blood tests, ultrasound, and a special liver scan (FibroScan) to check 200 adults. The goal is to understand if thyr…

This early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…

This early-stage study by Pfizer looks at how different levels of liver function affect the processing of a new drug called PF-07328948. About 26 adults with and without liver impairment will take a single tablet and stay at the clinic for 6 days for monitoring and blood tests. T…

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects ov…

This study enrolls adults with known or suspected endocrine (hormone gland) disorders, such as diabetes or thyroid disease, to help researchers learn more about these conditions. Participants will undergo medical exams, blood and imaging tests, and possibly genetic testing. The m…

This study is not testing a new drug or treatment. Instead, researchers want to make sure their lab tests and equipment give accurate and repeatable results when studying conditions like obesity, diabetes, heart disease, and bone loss. Up to 100 healthy volunteers and people with…

This early-stage study is testing how the drug radiprodil behaves in people with mild, moderate, or severe liver problems compared to healthy adults. About 40 participants will receive a single dose and be monitored for about a week. The goal is to see if liver impairment affects…

This study is looking for new blood markers that could show how much scarring (fibrosis) is in the liver of people with chronic liver disease. Researchers will compare these markers to current tests like FibroScan and liver biopsy. The goal is to find a more accurate and less inv…

This study looks at whether a 4-week low-calorie diet can reverse fatty liver disease in people who were born with low birth weight. Researchers will compare them to people born at normal weight, using MRI scans to measure liver fat before and after the diet. Only 8 participants …

This study looks at how often children with celiac disease also have fatty liver disease, and whether a gluten-free diet helps. Researchers will review medical records of 91 children to track changes before and after starting the diet. The goal is to better understand the link be…

This early-stage study tests an experimental drug called HEC169584 in 96 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and how the body processes it, not to treat any disease. Results will help guide future studies for non-alcoholic steatohepatitis (…

This early-stage study is testing an investigational drug called PF-08653944 in 26 adults, some with healthy livers and others with mild to severe liver impairment. Researchers want to see how liver function affects the way the body processes the drug and whether it is safe. Part…

This study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues.…

This study aims to understand how liver diseases like fatty liver, hepatitis B, fibrosis, and cirrhosis develop by analyzing individual liver cells and their spatial organization. Researchers will collect blood and discarded liver tissue from 240 patients undergoing surgery or bi…

This study is recruiting 710 adults with fatty liver disease or alcohol-related liver disease, with or without cirrhosis, to understand why some develop liver cancer. Researchers will analyze genetic markers, immune factors, and imaging data from routine liver biopsies and blood …

This study looks at how androgens (a type of sex hormone) might affect fatty liver disease in young women. Researchers will compare changes in liver fat and stiffness over time in 150 women with and without PCOS. The goal is to understand the connection, not to test a treatment.

This early-stage trial is testing whether a one-week course of diazoxide can reduce the production of new fat in the liver. The study involves 25 adults with obesity, insulin resistance, and fatty liver disease. Participants will take either the drug or a placebo and undergo bloo…

This study looks at how the hormone insulin controls blood sugar and fat in healthy adults and those at risk for type 2 diabetes. Researchers will give participants a single dose of a drug called alpelisib, which blocks some of insulin's effects, to see if the liver can still mak…

This study looks at how the body handles a single dose of the drug vepdegestrant in people with moderate to severe liver problems compared to healthy people. About 24 adults (ages 18-70) will take one pill and stay at the clinic for 11 days. The goal is to see if liver function a…

This study follows 240 adults with NASH-related cirrhosis to find better ways to detect early signs of liver failure, such as internal bleeding, fluid buildup, or confusion. Researchers will track health records and exams over time to improve monitoring. The goal is to understand…

This study will follow 1,200 liver transplant patients in France to understand why some people bleed heavily during surgery while others don't. Researchers will use advanced methods like machine learning to build better prediction tools. The goal is to help doctors manage bleedin…

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…

This study tests whether a simple electronic health record alert can help primary care doctors identify patients with fatty liver disease who may have advanced liver scarring. The alert prompts doctors to calculate a risk score and, if needed, order a special ultrasound to check …

This study looks at how certain gene regulators, called SUV420H1/2, affect fatty liver disease (NAFLD). Researchers will analyze data from 260 people and use lab models to see if blocking these genes could reduce liver fat and damage. The goal is to find a new way to treat this c…

This early-stage study tests a single dose of the experimental drug efimosfermin alfa in 30 healthy adults of Chinese, Japanese, and White/European ancestry. The goal is to check safety, how the body processes the drug, and immune reactions. Participants will not receive any trea…

This study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …

This study is re-examining 1,400 adults in Stockholm to find early signs and risk factors for heart, lung, and liver diseases. Participants will get advanced scans, blood tests, and questionnaires. The goal is to better understand how these diseases develop and how to predict the…

This study aims to find out how many adults in rural Bangladesh have metabolic fatty liver disease (MAFLD) and how it relates to their diet and metabolic health. Researchers will check 1,000 participants with physical exams, blood tests, and ultrasound. The goal is to gather basi…

This study looks at the genes in colon polyps from people with MASH (a type of fatty liver disease) compared to those without fatty liver. Researchers want to find specific gene patterns that might signal higher risk. About 100 adults already scheduled for polyp removal will dona…

This early-stage study is testing a single dose of an experimental drug called EDG-7500 in 32 adults. Some have mild or moderate liver problems, while others have normal liver function. Researchers want to see how the drug moves through the body and if it is safe in people with d…

This study looks at how the drug MK-1084 (calderasib) moves through the body in people with and without liver problems. Researchers will measure drug levels in the blood and check for side effects. About 58 adults will take a single dose and be monitored. The goal is to understan…

This study is creating a digital tool to help teenagers and young adults (ages 14-20) who have had or are waiting for a liver transplant as they move from pediatric to adult care. The tool helps patients and doctors track medication use and well-being from home, reducing hospital…

This study will follow 1,000 adults in Hong Kong who have both type 2 diabetes and a common fatty liver condition called MASLD. Researchers will collect health data and blood samples over time to see how the liver disease progresses and to find early markers of serious liver scar…

This study follows 35 people with severe obesity who are having mini-gastric bypass surgery. Researchers want to see how the surgery changes body composition and improves related health issues like type 2 diabetes, sleep apnea, high blood pressure, and fatty liver disease. The go…

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This study is testing a new single probe for FibroScan, a device that measures liver stiffness to assess disease. Researchers want to see if one probe can work as well as the current two-probe system. About 309 adults with chronic liver disease will take part across France and Ho…

This study is testing whether a simple neck ultrasound can predict dangerous drops in blood pressure after anesthesia in adults with chronic liver disease. Researchers will measure blood flow in the carotid artery before and after anesthesia in 35 patients. If the method works, i…

This study looks at how the hormone glucagon works in people with type 2 diabetes, with or without fatty liver disease. Researchers will give participants low and high doses of glucagon and use scans and blood tests to measure how the liver and heart respond. The goal is to under…

This study from Mayo Clinic looks at how inflammation in fat tissue may affect the liver in people with severe obesity. Researchers will measure liver stiffness and fat tissue markers in 60 adults before they have weight-loss surgery. The goal is to better understand why some peo…

This study is testing whether simple blood tests and a liver scan can accurately track liver disease progression in 500 people with type 2 diabetes. Participants will be followed over time to see if these non-invasive tools can replace liver biopsies for detecting advanced scarri…

This study looks at how mild and moderate liver problems change the way the body handles a single dose of the drug tasurgratinib. Researchers will compare 18 people with stable liver impairment to healthy volunteers matched by age, weight, race, and gender. The goal is to underst…

This early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the dr…

This study looks at whether a special MRI scan that measures muscle health and frailty can predict death or the need for a liver transplant in people with liver disease. Researchers will follow 1,200 patients who are already getting an MRI for routine care. The goal is to see if …

This study looks at how common non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH, are in Olmsted County, Minnesota. Researchers will follow 800 adults over time to better diagnose these conditions and see how they affect long-term health, including risks f…

This study looks at how tiny communication points inside liver cells (called MAMs) change in people with a fatty liver disease called MASH. Researchers will collect liver and blood samples from 20 adults having weight-loss surgery. The goal is to understand what goes wrong in the…

This study is looking at a specific gene, PNPLA3, in 600 adults with a type of fatty liver disease called MASLD. Participants are from Guadeloupe, French Guiana, and Réunion Island. Researchers want to see how common certain gene variants are and if they are linked to more severe…

This study looks at how the liver reacts to a sugar injection during bariatric surgery in people with obesity, comparing those with and without fatty liver disease (MASLD). Forty adults will receive either a sugar solution or salt water during surgery, and small tissue samples wi…

This early-stage study is testing how the drug TS-172 behaves in the bodies of people with mild or moderate liver impairment. Researchers will measure drug levels in the blood to see if liver function affects how the drug is processed. The study involves 24 Japanese adults and is…

This study tracks 1,000 patients undergoing major liver, pancreas, or bile duct surgery to see if the time it takes for their albumin levels to return to normal can predict complications and length of hospital stay. Albumin is a protein that drops after surgery due to inflammatio…

This study looks at how the body handles a single dose of the cancer drug olverembatinib in people with normal vs. impaired liver function. Researchers will measure drug levels and safety in 48 adults. The goal is to understand if liver problems require dose adjustments.

This study looks at how eating a lot of fructose (a type of sugar) changes the bacteria in your gut and affects your risk for type 2 diabetes and fatty liver. Thirty adults with obesity, diabetes, or fatty liver will eat a high-fructose or high-glucose diet for 12 days, then swit…

This study is checking how common liver disease (MASLD) is in people who survived breast or colorectal cancer. Researchers will use painless scans and blood tests instead of a liver biopsy. The goal is to find better ways to catch liver problems early in cancer survivors.

This study looks at 1,000 people with alcohol-related liver disease to understand how their genes and drinking habits together raise the risk of liver cancer. Researchers will analyze DNA and lifestyle factors to create a risk score that could help doctors decide who needs regula…

This study looks at how a drug called LY3537031 moves through the body in people with mild, moderate, or severe liver problems compared to healthy volunteers. About 32 adults will receive a single injection under the skin. The goal is to understand how liver function affects drug…

This study collects blood and urine samples from 500 people with alcoholic liver disease, heavy drinkers without liver disease, and healthy non-drinkers. The goal is to create a biorepository that researchers can use to study biomarkers and improve understanding of the disease. P…

This study aims to find genetic differences that make some people with fatty liver disease develop severe liver damage or cancer. Researchers will analyze DNA from 2880 adults, including those with advanced disease and healthy controls. The goal is to create better risk tests and…

This study is collecting and analyzing genetic, metabolic, and microbiome data from over 6,000 people with and without metabolic syndrome. The goal is to find biological markers that predict disease progression and help create personalized prevention and treatment plans. Particip…

This study looks at how certain genes increase the risk of liver cancer (hepatocellular carcinoma) in people with nonalcoholic fatty liver disease (NAFLD). Researchers will follow 500 adults aged 45-75 with NAFLD to understand how genetic factors and lifestyle interact. The goal …

This study uses tiny, lab-grown liver models (organoids) made from patient cells to understand how a specific gene variant (I148M of PNPLA3) contributes to non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Researchers will expose these mini-livers to fatty acid…

This study tests a program where doctors' offices help families who struggle to afford food get connected to community nutrition support. About 600 families with children aged 5-18 who have certain health conditions and receive Medicaid or SNAP will take part. The goal is to see …

This study looks at how genetic factors influence the risk of liver damage and heart problems in people with fatty liver disease. Researchers will enroll 2,500 blood donors aged 40-65 who are overweight or have related conditions like high blood sugar or high cholesterol. The goa…

This study tests a new care pathway for non-alcoholic fatty liver disease (NAFLD) in VA primary care. The pathway automatically identifies at-risk patients and educates providers. Researchers will compare this approach to usual care in 32 primary care teams to see if it increases…

This study looks at the social and economic challenges faced by people with chronic liver disease, like trouble paying for food or housing. Researchers will survey 400 patients and their doctors at Indiana University Health to find out what needs are most common and how patients …

This is the first time BAR502, an experimental drug for NASH (a serious liver condition), is being tested in humans. The study involves 52 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive either a single dose or multiple…

This study interviews 25 people with MASH (a fatty liver disease linked to metabolism) to learn about their expectations, attitudes, and unmet needs before and after joining a special heart-liver program. Participants will have two private interviews. The goal is to improve care …

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…

This study looks at the immune cells inside the liver of people with non-alcoholic fatty liver disease (NAFLD). The goal is to find differences between those with simple fatty liver and those with the more serious form, NASH, which can lead to cirrhosis and liver cancer. Research…

This study looks at how not having reliable access to healthy food affects liver disease severity in children with MASLD (a fatty liver condition). Researchers will track diet quality and liver health in 160 children aged 6–17. The goal is to understand if poor diet due to food i…

This study is testing a new MRI technology to see if it can accurately assess fatty liver disease without needing a liver biopsy. Researchers will scan 500 patients and compare the MRI results with traditional tests. If it works, it could make diagnosis and monitoring much easier…